Stockscreener 앱 받기
46.81
1.36%
0.646
전일 마감가:
$46.16
열려 있는:
$46.42
하루 거래량:
82,334
Relative Volume:
0.10
시가총액:
$2.68B
수익:
$665.13M
순이익/손실:
$64.50M
주가수익비율:
40.91
EPS:
1.1442
순현금흐름:
$185.87M
1주 성능:
+4.30%
1개월 성능:
+1.47%
6개월 성능:
+41.15%
1년 성능:
+26.97%
1일 변동 폭
$45.88
$46.89
1주일 범위
$44.51
$47.26
52주 변동 폭
$29.16
$57.65
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
명칭
Supernus Pharmaceuticals Inc
전화
301-838-2500
주소
9715 KEY WEST AVENUE, ROCKVILLE, MD
SUPN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
46.77 | 2.65B | 665.13M | 64.50M | 185.87M | 1.1442 |
|
ZTS
Zoetis Inc
|
118.20 | 52.03B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.49 | 45.40B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.635 | 42.13B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.80 | 34.19B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
484.52 | 20.88B | 3.08B | 1.24B | 1.07B | 25.61 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-09 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-07-30 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-09-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | 재개 | Jefferies | Buy |
| 2021-12-01 | 재개 | Jefferies | Buy |
| 2021-04-13 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-06-16 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | 재개 | Jefferies | Hold |
| 2019-11-08 | 다운그레이드 | Berenberg | Buy → Hold |
| 2019-11-07 | 다운그레이드 | Stifel | Buy → Hold |
| 2019-11-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-11-12 | 재확인 | B. Riley FBR | Buy |
| 2018-01-18 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | 업그레이드 | Janney | Neutral → Buy |
| 2017-11-08 | 업그레이드 | Stifel | Hold → Buy |
| 2017-10-19 | 개시 | FBR & Co. | Buy |
| 2017-09-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2017-07-17 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | 개시 | Janney | Neutral |
| 2017-06-01 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | 업그레이드 | Jefferies | Hold → Buy |
| 2015-11-05 | 재확인 | Northland Capital | Outperform |
| 2015-10-28 | 개시 | Northland Capital | Outperform |
모두보기
Supernus Pharmaceuticals Inc 주식(SUPN)의 최신 뉴스
Can Supernus Pharmaceuticals Inc. stock resist market sell offsRate Hike & Scalable Portfolio Growth Ideas - Newser
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Popularity With Investors Is Under Threat From Overpricing - 富途牛牛
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics ... - Enidnews.com
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference - GlobeNewswire
Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecasts - Yahoo! Finance Canada
Responsive Playbooks and the SUPN Inflection - news.stocktradersdaily.com
Is Supernus Pharmaceuticals Inc. stock overvalued by current metricsDay Trade & Free Accurate Trade Setup Notifications - BỘ NỘI VỤ
Supernus Pharmaceuticals Inc Stock Analysis and ForecastMerger & Acquisition Updates & Buy Sell Signal Notifications - earlytimes.in
Reversal Confirmed Inter Globe Finance Limited Stock Rallies Above MAStock Price Forecasts & High Return Capital Gain - earlytimes.in
Supernus Pharmaceuticals (SUPN) Is Down 17.4% After Raising 2025 Guidance Amid Margin and Supply Pressures – Has the Bull Case Changed? - Sahm
Is Supernus Pharmaceuticals Inc a good long term investmentChart Pattern Recognition & Small Budget Trading Portfolio - earlytimes.in
What analysts say about Supernus Pharmaceuticals Inc stockEconomic Data Impact & Outstanding Return Stocks - earlytimes.in
SUPN insider Form 4 shows 15,000-share option exercise at $12.98 - Stock Titan
Assessing Supernus Pharmaceuticals After FDA Pipeline News and 24% Jump in 2025 - Yahoo Finance
Healthcare Stocks Analysis 2025: COO & SUPN to Sell, HCA to BuyNews and Statistics - IndexBox
Assessing Supernus Pharmaceuticals (SUPN) Valuation as Shares Hold Steady Following Period of Range-Bound Trading - Sahm
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN) - Yahoo Finance
How Supernus Pharmaceuticals Inc. stock benefits from tech adoptionJuly 2025 Update & Expert Curated Trade Ideas - newser.com
Supernus to acquire depression drugmaker Sage - MSN
Why Supernus Pharmaceuticals Inc. stock could benefit from AI revolutionQuarterly Trade Summary & Growth Focused Entry Point Reports - newser.com
Understanding the Setup: (SUPN) and Scalable Risk - news.stocktradersdaily.com
Advanced analytics toolkit walkthrough for Supernus Pharmaceuticals Inc.Sell Signal & Expert Approved Trade Ideas - newser.com
Statistical indicators supporting Supernus Pharmaceuticals Inc.’s strengthJuly 2025 Earnings & Fast Moving Stock Watchlists - newser.com
Measuring Supernus Pharmaceuticals Inc.’s beta against major indices2025 Dividend Review & Technical Confirmation Trade Alerts - newser.com
Is Supernus Pharmaceuticals Inc. a candidate for recovery playJuly 2025 Price Swings & Capital Efficient Trade Techniques - newser.com
How Investors Are Reacting To Supernus Pharmaceuticals (SUPN) Raising 2025 Revenue Guidance Despite Net Losses - simplywall.st
Supernus at Jefferies Conference: Strategic Growth and Challenges By Investing.com - Investing.com Australia
SUPN: Strong CNS portfolio growth, supply challenges for Onapgo, and active business development focus - TradingView
[Form 4] SUPERNUS PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Long term hold vs stop loss in Supernus Pharmaceuticals Inc.2025 Macro Impact & Technical Confirmation Alerts - newser.com
Using data models to predict Supernus Pharmaceuticals Inc. stock movementJobs Report & Weekly Momentum Stock Picks - newser.com
How to monitor Supernus Pharmaceuticals Inc. with trend dashboardsWeekly Investment Summary & Community Consensus Stock Picks - newser.com
Supernus Pharmaceuticals (SUPN): Assessing Valuation After Q3 Revenue Growth and Raised Guidance Despite Net Loss - Sahm
Supernus Pharmaceuticals Inc (SUPN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Supernus Pharmaceuticals Inc 주식 (SUPN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Khattar Jack A. | President, CEO |
Oct 09 '25 |
Option Exercise |
25.30 |
81,250 |
2,055,625 |
1,266,478 |
| Khattar Jack A. | President, CEO |
Oct 09 '25 |
Sale |
50.57 |
59,900 |
3,029,336 |
1,206,578 |
| NEWHALL CHARLES W III | Director |
Oct 09 '25 |
Sale |
50.77 |
25,000 |
1,269,234 |
104,644 |
1.53%
0.86%
자본화:
|
볼륨(24시간):